Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.

Journal: JCO clinical cancer informatics
PMID: 40215447

Abstract

PURPOSE: Cetuximab (CET), targeting the epidermal growth factor receptor, is a systemic treatment option for patients with colorectal cancer. One known predictive factor for CET efficacy is the presence of CET-related rash; other putative toxicity factors include fatigue and nausea. Analysis of early CET-associated toxicities may reveal patient subpopulations that clinically benefit from long-term CET treatment.

Authors

  • Danielle Lilly Nicholls
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Maria C Xu
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Luna Zhan
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Divya Sharma
    Biostatistics Department, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Katrina Hueniken
    Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada; Krembil Research Institute, University Health Network, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kaitlyn Chiasson
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Mary Wahba
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • M Catherine Brown
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Benjamin Grant
    Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Jeremy Shapiro
    Cabrini Hospital and Monash University, Melbourne, VIC, Australia.
  • Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
  • John Simes
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Derek Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
  • Dongsheng Tu
    Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
  • Christopher O'Callaghan
    Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
  • Eric Chen
  • Geoffrey Liu
    Medical Oncology and Medical Biophysics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Keywords

External Resources

Popular Topics
Recent Journals